We have located links that may give you full text access.
Impact of reperfusion therapies on clot resolution and long-term outcomes in patients with pulmonary embolism.
Journal of Vascular Surgery. Venous and Lymphatic Disorders 2024 Februrary 17
OBJECTIVE: Major progress in reperfusion strategies has substantially improved the short-term outcomes of patients with pulmonary embolism (PE), however, up to 50% of patients report persistent dyspnea after acute PE.
METHODS: A retrospective study of the pulmonary embolism response team (PERT) registry and included patients with repeat imaging at 3 to 12 months. The primary outcome was to determine the incidence of residual pulmonary vascular obstruction (RPVO) following acute PE. Secondary outcomes included the development of PE recurrence, right ventricular (RV) dysfunction, chronic thromboembolic pulmonary hypertension (CTEPH), readmission, and mortality at 12 months.
RESULTS: A total of 382 patients were included and 107 patients received reperfusion therapies followed by anticoagulation. Patients who received reperfusion therapies including systemic thrombolysis, catheter-directed thrombolysis and mechanical thrombectomy presented with a higher vascular obstructive index (VOI, 47% vs 28%, p<0.001) and signs of right heart strain on echocardiogram (81% vs 43%, p<0.001) at the time of diagnosis. A higher absolute reduction in VOI (45% vs 26%, p<0.001, 95% CI 14.0-25.6), greater improvement in RV function (82% vs 65%, p=0.021), lower 12-month mortality rate (2% vs 7%, p=0.038) and readmission rate (33% vs 46%, p=0.031) were observed in the reperfusion group. No statistically significant differences were found between groups in the development of CTEPH (8% vs 5%, p=0.488) and PE recurrence (8% vs 6%, p=0.646).
CONCLUSIONS: We observed a favorable survival and greater improvement in clot resolution and RV function in patients treated with reperfusion therapies.
METHODS: A retrospective study of the pulmonary embolism response team (PERT) registry and included patients with repeat imaging at 3 to 12 months. The primary outcome was to determine the incidence of residual pulmonary vascular obstruction (RPVO) following acute PE. Secondary outcomes included the development of PE recurrence, right ventricular (RV) dysfunction, chronic thromboembolic pulmonary hypertension (CTEPH), readmission, and mortality at 12 months.
RESULTS: A total of 382 patients were included and 107 patients received reperfusion therapies followed by anticoagulation. Patients who received reperfusion therapies including systemic thrombolysis, catheter-directed thrombolysis and mechanical thrombectomy presented with a higher vascular obstructive index (VOI, 47% vs 28%, p<0.001) and signs of right heart strain on echocardiogram (81% vs 43%, p<0.001) at the time of diagnosis. A higher absolute reduction in VOI (45% vs 26%, p<0.001, 95% CI 14.0-25.6), greater improvement in RV function (82% vs 65%, p=0.021), lower 12-month mortality rate (2% vs 7%, p=0.038) and readmission rate (33% vs 46%, p=0.031) were observed in the reperfusion group. No statistically significant differences were found between groups in the development of CTEPH (8% vs 5%, p=0.488) and PE recurrence (8% vs 6%, p=0.646).
CONCLUSIONS: We observed a favorable survival and greater improvement in clot resolution and RV function in patients treated with reperfusion therapies.
Full text links
Related Resources
Trending Papers
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app